Toggle Main Menu Toggle Search

Open Access padlockePrints

A randomized, controlled trial of the effect of allopurinol on left ventricular mass index in hemodialysis patients

Lookup NU author(s): Professor Miles WithamORCiD



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).


Increased left ventricular mass index (LVMI) is associated with mortality in end-stage renal disease. LVMI regression may improve outcomes. Allopurinol has reduced LVMI in randomized controlled trials in chronic kidney disease, diabetes, and ischemic heart disease. This study investigated whether allopurinol would regress LVMI in hemodialysis patients.

Publication metadata

Author(s): Rutherford E, Ireland S, Mangion K, Stewart GA, MacGregor MS, Roditi G, Woodward R, Gandy SJ, Houston JG, Jardine AG, Rauchhaus P, Witham MD, Mark PB, Struthers AD

Publication type: Article

Publication status: Published

Journal: Kidney International Reports

Year: 2021

Volume: 6

Issue: 1

Pages: 146-155

Print publication date: 01/01/2021

Online publication date: 03/12/2020

Acceptance date: 02/10/2020

Date deposited: 13/12/2020

ISSN (electronic): 2468-0249

Publisher: Elsevier Inc.


DOI: 10.1016/j.ekir.2020.10.025


Altmetrics provided by Altmetric


Funder referenceFunder name
British Heart Foundation ( PG/12/72/29743 )
This trial was prospectively registered with (NCT01951404)